Related Experiment Videos

Stimulating the development of orphan (and other) vaccines

B Schwartz¹, N R Rabinovich

¹Centers for Disease Control and Prevention, Atlanta, GA, USA.

Emerging Infectious Diseases

|December 22, 1999

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.

Gynecologic oncology·2006

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

European journal of cancer (Oxford, England : 1990)·2006

How often should a port-A-cath be flushed?

Cancer investigation·2005

An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin.

Investigational new drugs·2005

HTS magnetometers for fetal magnetocardiography.

Neurology & clinical neurophysiology : NCN·2005

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2005

See all related articles